drugset / Trial / NCT03838783

Flexible Insulin Therapy Untethered Insulin Regimen in Avidly Exercising Patients With Type 1 Diabetes: FIT Untethered

NCT03838783 ↗

Phase 4 Unknown 30 enrolled LMC Diabetes & Endocrinology Ltd.
RandomizedCrossoverOpen-labelTreatment

Summary

The overall objective of this study is to evaluate glycemic control and patient-reported outcomes in patients with Type 1 diabetes (T1D) who use insulin degludec and continuous subcutaneous insulin infusion in a combination untethered regimen during moderate or high-intensity exercise.

Timeline

Start
2018-05-15
Primary completion
2019-04-30
Completion
2019-06-30

Outcome

Met primary endpoint

paper hybrid CSII regimen had a significantly longer time in blood glucose range of 4-10 mmol/L during the 6-h period from the start of both moderate-intensity PMID 32445738 ↗

paper mean difference 86 min [95% CI 61-147], p=0·005 PMID 32445738 ↗

paper high-intensity in-clinic exercise session (60 min [11-109], p=0·01; 66% [32] vs 50% [27]) PMID 32445738 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject insulin degludec Protein / enzyme biologic — —